Company profile: Antiva Biosciences
1.1 - Company Overview
Company description
- Provider of biopharmaceutical therapeutics targeting diseases caused by HPV infection, including ABI-2280, a topical prodrug designed to treat high-grade cervical intraepithelial neoplasias (HSIL, CIN 2,3) and high-risk HPV infections by blocking HPV replication and inducing apoptosis in infected cells.
Products and services
- HPV Therapeutics Development: A biopharmaceutical program that creates therapeutics for diseases caused by HPV infection, including agents that block HPV replication and induce apoptosis in infected cells
- HSIL and High-Risk HPV Treatment Focus: An HPV-specific therapeutic effort targeting high-grade cervical intraepithelial neoplasias (CIN 2,3) and high-risk HPV infections, emphasizing replication blockade and apoptosis-driven clearance of infected cells
- ABI-2280: A topical prodrug engineered to treat HSIL (CIN 2,3) and high-risk HPV infections by blocking HPV replication and inducing apoptosis in infected cells.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Antiva Biosciences
GenturaDx
HQ: United States
Website
- Description: Provider of molecular diagnostic solutions focused on making multiplexed molecular testing affordable and practical for any laboratory to perform. Offers the IDbox system and single-use cassette designed to circumvent barriers of cost, automation and performance, facilitating in-house lab testing for actionable results.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GenturaDx company profile →
Horizon Discovery
HQ: United Kingdom
Website
- Description: Provider of gene editing and gene modulation platforms and services, including the Pin-point Base Editing Platform for precise base changes, Dharmacon siRNA, shRNA, and CRISPR reagents, drug discovery screening services, pre-engineered cell lines, and Mimix cell line-derived molecular reference standards for research and clinical applications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Horizon Discovery company profile →
Vigene Biosciences
HQ: United States
Website
- Description: Provider of gene delivery technologies and cell and gene therapy CDMO solutions, offering research- and cGMP-grade AAV, lentivirus, and adenovirus products and custom services, including ready-to-ship genome-wide human cDNA ORFs on adenoviral or lentiviral, supporting therapy development and production to advance biomedical research and make gene therapy affordable.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vigene Biosciences company profile →
Ocean Ridge Biosciences
HQ: United States
Website
- Description: Provider of accurate, affordable, and information-rich genomic services to the Health Care and Life Science industries. A life science company in the research tools sector of biotechnology, headquartered in Deerfield Beach and centrally located within the South Florida metropolis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ocean Ridge Biosciences company profile →
Genoway
HQ: France
Website
- Description: Provider of genetically modified mouse, rat, and cell line models for preclinical research in biopharma and academia. Delivers humanized, knockin, and conditional knockout models and inducible, spatiotemporal gene control using RMCE, FLEx, SSR, TET system, and homologous recombination, enabling gene insertions, deletions, inversions and to predict the success of new therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genoway company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Antiva Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Antiva Biosciences
2.2 - Growth funds investing in similar companies to Antiva Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Antiva Biosciences
4.2 - Public trading comparable groups for Antiva Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →